Neurocrine Biosciences, Inc.
NBIX
Market Cap$14.07B
Close$
$237.33
69.7% upside
Current Fair Value
69.7% upsideUndervalued by 69.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.07 Billion |
|---|---|
| Enterprise Value | $12.98 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $2.47 |
| Beta | 0.37 |
| Outstanding Shares | 100,637,227 |
| Avg 30 Day Volume | 805,973 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 56.36 |
|---|---|
| PEG | -35.97 |
| Price to Sales | 7.36 |
| Price to Book Ratio | 6.08 |
| Enterprise Value to Revenue | 6.55 |
| Enterprise Value to EBIT | 27.6 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
ESG Score
No data
About Neurocrine Biosciences, Inc.
CEO: Kevin Gorman